Infant neutropenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of hiv
| dc.contributor.author | Njuguna, Irene | |
| dc.contributor.author | Marie, Reilly | |
| dc.contributor.author | Walter, Jaoko | |
| dc.contributor.author | Gichuhi, Christine | |
| dc.contributor.author | Gwen, Ambler | |
| dc.contributor.author | Elizabeth, Maleche-Obimbo | |
| dc.contributor.author | Barbara, Lohman-Payne | |
| dc.contributor.author | Hanke, Tomáš | |
| dc.contributor.author | John-Stewart, Grace | |
| dc.date.accessioned | 2015-02-11T13:29:32Z | |
| dc.date.available | 2015-02-11T13:29:32Z | |
| dc.date.issued | 2014 | |
| dc.identifier.uri | http://hdl.handle.net/11295/80222 | |
| dc.description.abstract | Maternal antiretroviral treatment (ART) is recommended for prevention of mother-to-child HIV-1 transmission (PMTCT), including in women with high CD4+ cell counts. Within a pediatric HIV-1 vaccine trial PedVacc 002, we assessed hematologic profiles of infants born to mothers receiving ART. All mothers had CD4+ cell counts of >350 mm-3; 93% received zidovudine-containing ART; infants received nevirapine up to 6 weeks and cotrimoxazole after 6 weeks. Among 84 infants at 19 weeks, 58% had hematologic toxicity; 44% had neutropenia and 23% had anemia. Breastfeeding was associated with 3.8-fold higher risk of neutropenia (RR 3.8, 95% CI 1.03-14.1, p = 0.008). Hematologic monitoring and PMTCT regimen selection are important for optimizing infant outcomes | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | University of Nairobi | en_US |
| dc.title | Infant neutropenia associated with breastfeeding during maternal antiretroviral treatment for prevention of mother-to-child transmission of hiv | en_US |
| dc.type | Article | en_US |
| dc.type.material | en | en_US |
Files in this item
This item appears in the following Collection(s)
-
Faculty of Health Sciences (FHS) [10378]